Extension of Kalydeco (Ivacaftor) Update
CFI have been informed that some news about the extension of Kalydeco (Ivacaftor), which is currently undergoing a Health Technology Assessment (HTA), is due to be posted on the website of the NCPE (National Centre for Pharmacoeconomics) around the 12 October or shortly after. The extension application includes commencing treatment of those already on Kalydeco to 2 years and over (children with CF who have the G551D gene alteration are currently 6 years old when treatment commences). The extension also covers other class 111 gating mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R, as listed on the NCPE website.
Please note that this news item should not be confused with the Orkambi negotiations. These negotiations are still on going and we are at an important stage.